Swamy Yeleswaram's most recent trade in Rapport Therapeutics Inc. was a trade of 20,225 Common Stock done at an average price of $40.0 . Disclosure was reported to the exchange on April 17, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Rapport Therapeutics Inc | Swamy Yeleswaram | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 39.99 per share. | 17 Apr 2026 | 20,225 | 246,426 | - | 40.0 | 808,844 | Common Stock |
| Rapport Therapeutics Inc | Swamy Yeleswaram | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 35.08 per share. | 10 Apr 2026 | 10,200 | 266,651 | - | 35.1 | 357,797 | Common Stock |
| Rapport Therapeutics Inc | Swamy Yeleswaram | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 34.97 per share. | 10 Apr 2026 | 9,165 | 276,851 | - | 35.0 | 320,537 | Common Stock |
| Rapport Therapeutics Inc | Swamy Yeleswaram | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 34.98 per share. | 10 Apr 2026 | 500 | 286,016 | - | 35.0 | 17,490 | Common Stock |
| Rapport Therapeutics Inc | Swamy Yeleswaram | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 34.90 per share. | 08 Apr 2026 | 360 | 286,516 | - | 34.9 | 12,564 | Common Stock |
| Rapport Therapeutics Inc | Swamy Yeleswaram | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 29.99 per share. | 25 Mar 2026 | 10,115 | 286,876 | - | 30.0 | 303,355 | Common Stock |
| Rapport Therapeutics Inc | Swamy Yeleswaram | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2026 | 120,000 | 120,000 | - | - | Stock Option (Right to Buy) | |
| Rapport Therapeutics Inc | Swamy Yeleswaram | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Dec 2025 | 9,000 | 299,831 | - | - | Common Stock | |
| Rapport Therapeutics Inc | Swamy Yeleswaram | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 30.05 per share. | 31 Dec 2025 | 2,840 | 296,991 | - | 30.1 | 85,342 | Common Stock |
| Rapport Therapeutics Inc | Swamy Yeleswaram | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2025 | 110,000 | 110,000 | - | - | Stock Option (Right to Buy) | |
| Rapport Therapeutics Inc | Swamy Yeleswaram | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2024 | 84,904 | 84,904 | - | - | Stock Option (Right to Buy) |